Previous 10 | Next 10 |
U.S.-listed shares of DBV Technologies (NASDAQ:DBVT) soared nearly 40% to $2.14 in Tuesday aftermarket trading, after the company said its phase 3 trial assessing its Viaskin Peanut for the treatment of peanut allergies in toddlers aged 1 to 3 years met its main goal. Viaskin Peanut...
Gainers: DBV Technologies (DBVT) +48%. Biodesix (BDSX) +15%. Intel Corporation (INTC) +7%. Limoneira (LMNR) +6%. Groupon (GRPN) +5%. Losers: Redbox Entertainment (RDBX) -5%. C4 Therapeutics (CCCC) -5%. Kezar Life Sciences (KZR) -5%. Iris Energy Limited (IREN) -5%. LumiraDx Lim...
Montrouge, France, June 7, 2022 DBV Technologies Announce s Positive Topline Results from Phase 3 EPITOPE T rial of Viaskin Peanut in Peanut - Allerg ic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE E...
Montrouge, France, May 12, 2022 DBV Technologies Announces Results of I ts 2022 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed Re solutions DBV Technologies (Euronext: DBV – ISI...
Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $ 15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “C...
3 Hot Penny Stocks to Add to Your Watchlist Right Now Recently, we’ve seen major volatility with both penny stocks and blue chips. While volatility can be used as an advantage, for those without a well-thought-out trading strategy, it can be detrimental. If you’re inte...
DBV Technologies S.A. (DBVT) Q1 2022 Results Conference Call May 02, 2022 05:00 PM ET Company Participants Anne Pollak - Head, IR Daniel Tassé - CEO Conference Call Participants Jon Wolleben - JMP Securities Presentation Operator Welcome to the DBV Technologies First Quarter 2022 Earning...
Montrouge, France, May 2, 2022 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological company, ...
DBV Technologies press release (NASDAQ:DBVT): Q1 GAAP EPS of -$0.30 beats by $0.10. Revenue of $2.55M (-13.3% Y/Y) beats by $1.27M. For further details see: DBV Technologies GAAP EPS of -$0.30 beats by $0.10, revenue of $2.55M beats by $1.27M
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45 th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa...
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 *...